Genmab to Sell US Plant and Cut 300 Jobs
In an attempt to save around $60 million annually, the Danish biopharmaceutical company Genmab is planning to sell its manufacturing facility located in Brooklyn Park, MN, and reduce headcount by approximately 300 positions.
In an attempt to save around $60 million annually, the Danish biopharmaceutical company Genmab is planning to sell its manufacturing facility located in Brooklyn Park, MN, and reduce headcount by approximately 300 positions.
The company will reduce staff across its international locations in an effort to work in as cost effective a manner as possible. Going forward, it will adopt a business model based on contracts with vendors to address clinical development work requirements.
Genmab said it did not intend to discontinue any current development programs and would continue to focus on creating antibodies with the potential to treat cancer.
Genmab bought the Brooklyn Park facility in early 2008 from PDL BioPharma for $240 million cash at a time when it found manufacturing capacity scarce. The facility will now operate on a maintenance-only mode with a small staff, until a sale is agreed.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
